```html

Zollinger‑Ellison Syndrome (ZES) – A Comprehensive Patient Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas develop in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, which in turn stimulates the stomach to produce large volumes of acid. The resulting hyper‑acidic environment can damage the lining of the stomach and duodenum, leading to severe peptic ulcers.

Who it affects: ZES can occur at any age but most commonly presents in adults between 30 and 60 years. Both men and women are affected, though a slight male predominance (approximately 55 % male) has been reported.

Prevalence: The condition is extremely uncommon, affecting roughly 1–3 persons per million worldwide. About 20–30 % of cases are associated with a hereditary condition called Multiple Endocrine Neoplasia type 1 (MEN‑1).

Symptoms

Symptoms result from chronic excess stomach acid and from the tumor itself. They may develop gradually, so early signs are often missed.

Gastro‑intestinal symptoms

• Recurrent abdominal pain – often described as burning or gnawing, typically worsens 1–3 hours after meals.
• Persistent or worsening heartburn – not relieved by over‑the‑counter antacids.
• Diarrhea – occurs in up to 60 % of patients; stools may be watery, greasy, and foul‑smelling because acid inactivates pancreatic enzymes.
• Nausea & vomiting – especially after large meals.
• Gastro‑intestinal bleeding – manifested as melena (black, tarry stools) or hematemesis (vomiting blood) from ulcer erosion.

Ulcer‑related symptoms

• Multiple peptic ulcers that are refractory (do not heal) despite standard proton‑pump inhibitor (PPI) therapy.
• Ulcers located outside the usual duodenal “first part”—often in the jejunum or even the ileum.
• Perforation of an ulcer, leading to sudden, severe abdominal pain.

Systemic symptoms

• Weight loss – secondary to malabsorption and chronic diarrhea.
• Fatigue – from anemia due to chronic blood loss.
• Signs of MEN‑1 – such as hyperparathyroidism (kidney stones, bone pain) or pituitary tumors (headaches, vision changes).

Causes and Risk Factors

ZES is caused by a gastrin‑secreting neuroendocrine tumor. The cause is usually divided into two categories.

1. Sporadic gastrinomas

• Most cases (≈70 %) are sporadic, meaning no clear inherited mutation is identified.
• These tumors arise from enterochromaffin‑like (ECL) cells in the duodenum or pancreas.

2. MEN‑1‑associated gastrinomas

• MEN‑1 is an autosomal dominant syndrome caused by mutations in the MEN1 tumor suppressor gene.
• Patients with MEN‑1 have a 10‑fold higher risk of developing gastrinomas compared with the general population.
• Other endocrine tumors in MEN‑1 (parathyroid, pituitary) often coexist.

Risk Factors

• Family history of MEN‑1 or other neuroendocrine tumor syndromes.
• Age > 30 years (most cases diagnosed after this age).
• Chronic use of proton‑pump inhibitors does not cause ZES, but can mask early symptoms and delay diagnosis.

Diagnosis

Because ZES mimics common acid‑related disorders, a high index of suspicion is essential. Diagnosis combines biochemical testing, imaging, and endoscopic evaluation.

1. Biochemical Confirmation

• Fasting serum gastrin level – a level > 1000 pg/mL (≈10 × upper limit of normal) is highly suggestive, especially when accompanied by low gastric pH (< 2). Even modest elevations (200–500 pg/mL) may be diagnostic if gastric pH is low.
• Secretin stimulation test – intravenous secretin paradoxically raises gastrin > 120 pg/mL in ZES, whereas it suppresses gastrin in other conditions.

2. Localization of the Tumor

• Endoscopic ultrasound (EUS) – high‑resolution imaging of the pancreas and duodenum; sensitivity up to 85 % for tumors < 2 cm.
• Multiphasic contrast‑enhanced CT or MRI – identifies larger lesions and assesses liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – detects neuroendocrine tumors that express somatostatin receptors; preferred for staging.
• Selective arterial secretin stimulation test – used when imaging is inconclusive; measures gastrin rise after selective arterial secretin injection.

3. Endoscopic Evaluation

• Upper endoscopy (EGD) – visualizes ulcers, allows biopsies to rule out Helicobacter pylori or malignancy, and may reveal large, multiple ulcers typical of ZES.

4. Histopathology

If a tumor is resected, pathology confirms a neuroendocrine tumor (NET) with immunohistochemical staining for gastrin, chromogranin A, and synaptophysin.

Treatment Options

Management targets two goals: control gastric acid hypersecretion and eradicate or control the tumor(s). A multidisciplinary team—gastroenterology, surgery, oncology, endocrinology—is ideal.

Acid‑suppression therapy (first line)

• High‑dose Proton‑Pump Inhibitors (PPIs) – e.g., omeprazole 60 mg twice daily or esomeprazole 40 mg twice daily. Doses are often higher than for typical GERD.
• PPIs control symptoms in > 90 % of patients and promote ulcer healing.
• Long‑term monitoring is needed for potential side effects (e.g., hypomagnesemia, B12 deficiency).

Surgical treatment

• Curative resection – indicated when the tumor is localized and resectable (usually duodenal gastrinomas < 2 cm). Options include pancreas‑sparing duodenectomy, enucleation, or Whipple procedure for larger pancreatic lesions.
• In MEN‑1 patients, surgery is more controversial because of multifocal disease; the benefit must be weighed against operative risk.

Medical therapy for tumor control

• Somatostatin analogs (octreotide LAR or lanreotide) – bind somatostatin receptors, reducing gastrin secretion and sometimes shrinking tumor size. Effective in 50‑70 % of patients.
• Targeted therapy – everolimus (an mTOR inhibitor) and sunitinib (a tyrosine‑kinase inhibitor) are FDA‑approved for advanced, progressive pancreatic NETs.
• Chemotherapy – limited role; used for high‑grade, rapidly proliferating NETs.

Management of metastases

• Liver‑directed therapies – radiofrequency ablation, transarterial chemoembolization (TACE), or selective internal radiation therapy (SIRT) for hepatic metastases.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE delivers targeted radiation; improves progression‑free survival in metastatic NETs.

Lifestyle and supportive measures

• Avoid NSAIDs, aspirin, and alcohol, which aggravate ulcer formation.
• Small, frequent meals may reduce post‑prandial acid spikes.
• Supplement vitamin B12 and magnesium if on chronic high‑dose PPIs.

Living with Zollinger‑Ellison Syndrome

While ZES is chronic, most patients can lead active lives with proper treatment.

Medication adherence

• Take PPIs exactly as prescribed—timing (usually 30 minutes before meals) matters.
• Keep a medication diary, especially when dose adjustments are made.

Monitoring & follow‑up

• Serum gastrin levels every 6‑12 months (or sooner if symptoms change).
• Annual imaging (CT/MRI or DOTATATE PET) to detect recurrence or metastasis.
• Endoscopic surveillance every 2‑3 years, or sooner after ulcer complications.

Nutrition

• High‑protein, low‑fat diet to aid nutrient absorption.
• Consider pancreatic enzyme supplements if steatorrhea (fatty stools) occurs.
• Stay hydrated; diarrhea can lead to electrolyte loss.

Psychosocial support

• Join support groups (e.g., NET Patient Foundation) to share experiences.
• Seek counseling if anxiety or depression arises from chronic illness.

Prevention

Because ZES is largely driven by genetic mutations, primary prevention is limited. However, the following steps can reduce complications and facilitate early detection:

• For individuals with a known MEN1 mutation: undergo regular screening (annual gastrin level, imaging) as recommended by a genetics specialist.
• Avoid long‑term, high‑dose NSAIDs or aspirin unless prescribed, as they increase ulcer risk.
• Manage Helicobacter pylori infection promptly—while it does not cause ZES, co‑infection worsens ulcer disease.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Recurrent, perforated peptic ulcers – can cause peritonitis and require emergency surgery.
• Gastrointestinal bleeding – may lead to anemia or require transfusion.
• Malabsorption & severe diarrhea – resulting in weight loss, electrolyte disturbances, and reduced quality of life.
• Metastatic disease – about 25‑30 % of sporadic gastrinomas metastasize, most often to the liver or regional lymph nodes.
• Gastric hyperplasia or carcinoid tumors – chronic acid exposure can stimulate gastric mucosal changes.
• Bone loss – chronic PPI use may impair calcium absorption; combine with MEN‑1‑related hyperparathyroidism can increase fracture risk.

When to Seek Emergency Care

---

References: Mayo Clinic, Zollinger‑Ellison Syndrome; NIH National Institute of Diabetes and Digestive and Kidney Diseases, ZES Overview; American Cancer Society, Neuroendocrine Tumors; WHO Classification of Tumours of the Digestive System, 5th Edition; Cleveland Clinic, Zollinger‑Ellison Syndrome; Journal of Clinical Endocrinology & Metabolism, 2022; Gut 2021; NCCN Guidelines for Neuroendocrine Tumors, Version 2023.

```